key: cord-0831995-dhb8zrgk authors: Piaserico, Stefano; Gisondi, Paolo; Cazzaniga, Simone; Naldi, Luigi title: Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy date: 2020-08-18 journal: Am J Clin Dermatol DOI: 10.1007/s40257-020-00552-w sha: 017ea51c4755cfd6ae26d8445eb44f6bf48c7ee9 doc_id: 831995 cord_uid: dhb8zrgk nan inhibitors. Over the period analyzed, all patients were recommended not to modify their treatment regimen. The COVID-19 incidence rate (IR) was 9.7 (95% CI 3.9-20.1) per 10,000 person-months in our cohort and 11.5 (95% CI 11.4-11.7) per 10,000 person-months in the general regional population, resulting in an incidence rate difference (IRD) of − 1.8 (95% CI − 7.6 to 8.6). The IR of hospitalization for COVID-19-related pneumonia and COVID-19-related death were 6.5 (95% CI 2.0-15.6) and 0 (95% CI 0-10.4) per 10,000 person-months in our cohort and 9.6 (95% CI 9.4-9.7) and 1.16 (95% CI 1.10-1.21) per 10,000 person-months in the general population, resulting in an IRD of − 3.1 (95% CI − 7.5 to 6.0) and − 1.2 (95% CI − 2.6 to 3.7), respectively. There were only six cases of COVID-19 among 1830 psoriatic patients compared with 19,154 cases among 4,905,854 individuals (16,601,409.94 person-months) from the general population. Out of the six cases of COVID-19, four were admitted to hospital because of interstitial pneumonia. None of them died. The patients were treated with etanercept, ustekinumab, ixekizumab, secukinumab, and guselkumab. In our large cohort of psoriatic patients, no signal emerged for an increased risk of COVID-19 or COVID-19-related respiratory or life-threatening complications associated with biologics. Our analysis was flawed by low numbers of patients with COVID-19 in our cohort. Nonetheless, our cohort of psoriatic patients had a higher prevalence of comorbidities compared with the general population, including hypertension (25.9% vs 17%), diabetes mellitus (13.8% vs 4.5%), and cardiovascular diseases (12.2 vs 4.3%). All of these conditions have been associated with a significantly increased rate of hospitalization and fatal course in COVID-19 patients [5] . Therefore, a higher incidence of COVID-19-related hospitalization and death would have been expected in our psoriasis patients. This further corroborates the hypothesis of at least similar or lower risk of COVID-19 pneumonia and death in our psoriatic patients treated with biologics compared with the general population. Accordingly, some preliminary data on TNF inhibitors and IL-12/23 inhibitors in inflammatory bowel disease patients showed that these therapies do not worsen the clinical course of COVID-19 compared with sulfasalazine/ mesalamine [6] . On the other hand, they seem to be associated with a better outcome, even though there are insufficient data to make definite statements [6] . Our data confirms the findings of a recent paper from Northern Italy [7] . In our study, however, we focus on the Veneto Region where one of the first Italian outbreaks of COVID occurred. Moreover, we extended the follow-up time to 1 June, 2020. We could therefore perform a comparison with the general population of the same region, calculating incidence rate differences, which were not assessed in the previous paper. This study has some limitations. Despite a reasonablysized cohort of 1830 psoriatic patients receiving biologic treatment, we collected very few COVID-19 cases, with wide CIs. Given the small event count, we could not stratify the analysis by type of biologic therapy. While awaiting evidence directing the treatment of COVID-19, we have to make decisions on our patients undertaking biological therapies. The data available so far do not indicate an increased risk of COVID-19 infection or COVID-19-related pneumonia and death in these patients. Conflict of Interest Stefano Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Novartis, Pfizer, Sandoz, and UCB. Simone Cazzaniga has nothing to declare. Luigi Naldi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Eli Lilly, and Novartis. Funding The article has no funding source. Consent to Participate Not applicable (data were anonymized). Not applicable (data were anonymized). The datasets generated during the current study are available from the corresponding author on reasonable request. Author Contributions Stefano Piaserico conceived and planned the study, interpreted the data and drafted the manuscript. Paolo Gisondi conceived and planned the study, interpreted the data and critically reviewed the manuscript. Simone Cazzaniga analyzed the data and drafted the manuscript. Luigi Naldi conceived and planned the study, interpreted the data and critically reviewed the manuscript. 252 (13.8) 220,763 (4.5) COVID-19 incidence rate per 10,000 person-months (95% CI) 9.7 (3.9-20.1) 11.5 (11.4-11.7) COVID-19-related hospitalizations per 10,000 person-months (95% CI) 4 (2.0-15.6) 9.6 (9.4-9.7) COVID-19-related deaths per 10,000 person-months (95% CI) 0 (0-10.4) 1.16 (1.10-1.21) The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials COVID-19: a case for Inhibiting IL-17? Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis SECURE-IBD database public data update The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience ISTAT census data. 2020 Veneto Regional Health Agency. Data on COVID-19 confirmed cases Data on COVID-19 confirmed cases